login
login

Europe Daily Bulletin No. 13079

8 December 2022
Contents Publication in full By article 25 / 39
EU RESPONSE TO COVID-19 / Health
EMA says that bivalent vaccines adapted to BA.4 and BA.5 can be used for primary vaccination
Brussels, 07/12/2022 (Agence Europe)

On Tuesday 6 December, the Emergency Task Force (ETF) of the European Medicines Agency (EMA) issued a statement in which it considers that bivalent messenger RNA vaccines adapted to both the BA.4 and BA.5 strains of SARS-CoV-2 and the original strain of the virus, which have so far been used for booster vaccination, can be used to complete a primary vaccination course.

The ETF reviewed laboratory studies and data indicating that the immune response to these adapted bivalent vaccines in...

Contents

Russian invasion of Ukraine
ECONOMY - FINANCE
SECTORAL POLICIES
FUNDAMENTAL RIGHTS - SOCIETAL ISSUES
SOCIAL AFFAIRS
EXTERNAL ACTION
INSTITUTIONAL
EU RESPONSE TO COVID-19
COURT OF JUSTICE OF THE EU
NEWS BRIEFS